| FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors |
113 |
| Oxidative Phosphorylation as an Emerging Target in Cancer Therapy |
106 |
| WNT/beta-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers |
87 |
| Clinical Significance of PD-L1(+) Exosomes in Plasma of Head and Neck Cancer Patients |
78 |
| Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade |
77 |
| PRMT5 Circular RNA Promotes Metastasis of Urothelial Carcinoma of the Bladder through Sponging miR-30c to Induce Epithelial-Mesenchymal Transition |
70 |
| Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study |
67 |
| Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer |
66 |
| Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers |
65 |
| Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes |
65 |
| CAR T Cells Targeting B7-H a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors |
64 |
| Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer |
63 |
| The Advantage of FLASH Radiotherapy Confirmed in Mini-pig and Cat-cancer Patients |
63 |
| False-Positive Plasma Genotyping Due to Clonal Hematopoiesis |
62 |
| T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma |
61 |
| Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients |
60 |
| Breast Cancer Immunotherapy: Facts and Hopes |
57 |
| Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers |
57 |
| Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies |
57 |
| Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF beta, in Advanced Solid Tumors |
56 |
| Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA |
54 |
| Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis |
53 |
| The Role of Angiogenesis in Hepatocellular Carcinoma |
52 |
| Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial |
51 |
| Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC |
51 |
| Long Noncoding RNA LINC01234 Functions as a Competing Endogenous RNA to Regulate CBFB Expression by Sponging miR-204-5p in Gastric Cancer |
51 |
| Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies |
51 |
| Residual Convolutional Neural Network for the Determination of IDH Status in Low- and High-Grade Gliomas from MR Imaging |
51 |
| High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden |
51 |
| Long Noncoding RNA NEAT Regulated by the EGFR Pathway, Contributes to Glioblastoma Progression Through the WNT/beta-Catenin Pathway by Scaffolding EZH2 |
48 |
| Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab |
47 |
| Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer |
47 |
| Deep Learning Predicts Lung Cancer Treatment Response from Serial Medical Imaging |
47 |
| Age Correlates with Response to Anti-PD Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations |
46 |
| The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 807 Advanced Cancer Patients |
46 |
| Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy |
45 |
| FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia |
45 |
| Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index |
45 |
| TP STK and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma |
44 |
| LncRNA-FEZFl-AS1 Promotes Tumor Proliferation and Metastasis in Colorectal Cancer by Regulating PKM2 Signaling |
44 |
| Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations |
44 |
| Prognostic Significance of Tumor-Infiltrating B Cells and Plasma Cells in Human Cancer |
44 |
| Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3(+) Regulatory T Cells (Tregs) in Human Cancers |
43 |
| DICER1 and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategies |
43 |
| Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer |
43 |
| Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention |
43 |
| Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 thorn Breast Cancer Metastasis to the Brain |
43 |
| Radiomics of Multiparametric MRI for Pretreatment Prediction of Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer: A Multicenter Study |
42 |
| Focal Irradiation and Systemic TGF beta Blockade in Metastatic Breast Cancer |
42 |
| CD103(+) Tumor-Resident CD8(+) T Cells Are Associated with Improved Survival in Immunotherapy-Naive Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment |
41 |
